9 Meters Biopharma Net Income

As of the most recent data (March 2023), NMTR shows a net income of $-50M. That compares with $-43M in the prior-year period — down 16.7% year over year. That is below the Technology sector average of $6.3T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NMTR's net income is now $-50M (was $-43M) — a 16.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether 9 Meters Biopharma is outperforming or lagging.

The Technology sector average net income is about $6.3T. 9 Meters Biopharma is at $-50M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how NMTR stacks up against individual peers as well.

Tracking NMTR's net income over time shows whether 9 Meters Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-50M That compares with $-43M in the prior-year period — down 16.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has 9 Meters Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-50M) with ownership activity and broader fundamentals.